FDA Approves Lilly’s Taltz for Another Use

Lilly completed the CoLucid acquisition in March.

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has received another approval from the U.S. Food and Drug Administration for Taltz. The drug, a treatment for plaque psoriasis, can now also be used for the treatment of arthritis known as ankylosing spondylitis in adults.

Lilly says AS can cause severe back pain and can impact a patient’s mobility if left untreated. The company says it affects 1.6 million people in the U.S.

"We are excited to now offer Taltz as a treatment option for people in need of relief from the symptoms of AS. This approval further underscores Lilly’s commitment to helping people living with rheumatic diseases."

The pharmaceutical company says this is the third approved use for Taltz, which the FDA first approved in 2016 as a treatment for moderate to severe plaque psoriasis in adult patients. The FDA then gave approval in 2017 for Taltz to be used to treat active psoriatic arthritis.

Taltz can be self-administered through an injection.